FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2114819486> ?p ?o ?g. }

• W2114819486 endingPage "666" @default.
• W2114819486 startingPage "657" @default.
• W2114819486 abstract "To investigate the activity of etoposide, doxorubicin, and cisplatin plus mitotane in the management of advanced adrenocortical carcinoma (ACC) patients, 72 patients with measurable disease not amenable to radical surgery were enrolled in a prospective, multicenter phase II trial. EDP schedule (etoposide 100 mg/m 2 on days 5–7, doxorubicin 20 mg/m 2 on days 1 and 8, and cisplatin 40 mg/m 2 on days 1 and 9) was administered intravenously every 4 weeks. Concomitantly, patients were given up to 4 g/day of oral mitotane. Five patients achieved a complete response and 30 a partial response, for an overall response rate of 48.6% (95% CI: 37.1–60.3). Median time to progression in responding patients was 18 months. The EDP regimen was well tolerated, leukopenia being the dose limiting toxicity. One toxic related death due to septic shock, however, was registered. Radical surgical resection of residual disease after chemotherapy was performed in 10 patients. The overall survival of patients attaining a disease free status (clinical complete responders+radically resected) was significantly higher than that of patients with partial response or no response ( P <0.002). Androgen secretion was associated with long survival, while glucocorticoid secretion was associated with poor prognosis both in univariate and multivariate analysis. In conclusion, EDP plus mitotane is an active and manageable combination scheme for ACC patients. Surgical resection of residual disease subsequent to chemotherapy leads to a more favourable outcome. The natural history of the disease is significantly influenced by the secretory status of the tumor." @default.
• W2114819486 created "2016-06-24" @default.
• W2114819486 creator A5003946700 @default.
• W2114819486 creator A5005729599 @default.
• W2114819486 creator A5005843927 @default.
• W2114819486 creator A5023991037 @default.
• W2114819486 creator A5024263685 @default.
• W2114819486 creator A5029415642 @default.
• W2114819486 creator A5037744319 @default.
• W2114819486 creator A5044446755 @default.
• W2114819486 creator A5050426287 @default.
• W2114819486 creator A5057499299 @default.
• W2114819486 creator A5065065990 @default.
• W2114819486 creator A5077674568 @default.
• W2114819486 creator A5083745890 @default.
• W2114819486 date "2005-09-01" @default.
• W2114819486 modified "2023-10-18" @default.
• W2114819486 title "Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial" @default.
• W2114819486 cites W1965293262 @default.
• W2114819486 cites W1971984314 @default.
• W2114819486 cites W1987174700 @default.
• W2114819486 cites W1991690093 @default.
• W2114819486 cites W2003238497 @default.
• W2114819486 cites W2029409133 @default.
• W2114819486 cites W2039383576 @default.
• W2114819486 cites W2040572070 @default.
• W2114819486 cites W2044004262 @default.
• W2114819486 cites W2044828697 @default.
• W2114819486 cites W2065554335 @default.
• W2114819486 cites W2066809274 @default.
• W2114819486 cites W2079874148 @default.
• W2114819486 cites W2089304791 @default.
• W2114819486 cites W2091167305 @default.
• W2114819486 cites W2091480567 @default.
• W2114819486 cites W2095310757 @default.
• W2114819486 cites W2096859456 @default.
• W2114819486 cites W2107542049 @default.
• W2114819486 cites W2128940612 @default.
• W2114819486 cites W2167805334 @default.
• W2114819486 cites W2223265747 @default.
• W2114819486 cites W2296141719 @default.
• W2114819486 cites W2336089418 @default.
• W2114819486 cites W2337432642 @default.
• W2114819486 cites W2430030498 @default.
• W2114819486 cites W2475190594 @default.
• W2114819486 cites W3141275090 @default.
• W2114819486 cites W50763653 @default.
• W2114819486 doi "https://doi.org/10.1677/erc.1.01025" @default.
• W2114819486 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16172198" @default.
• W2114819486 hasPublicationYear "2005" @default.
• W2114819486 type Work @default.
• W2114819486 sameAs 2114819486 @default.
• W2114819486 citedByCount "261" @default.
• W2114819486 countsByYear W21148194862012 @default.
• W2114819486 countsByYear W21148194862013 @default.
• W2114819486 countsByYear W21148194862014 @default.
• W2114819486 countsByYear W21148194862015 @default.
• W2114819486 countsByYear W21148194862016 @default.
• W2114819486 countsByYear W21148194862017 @default.
• W2114819486 countsByYear W21148194862018 @default.
• W2114819486 countsByYear W21148194862019 @default.
• W2114819486 countsByYear W21148194862020 @default.
• W2114819486 countsByYear W21148194862021 @default.
• W2114819486 countsByYear W21148194862022 @default.
• W2114819486 countsByYear W21148194862023 @default.
• W2114819486 crossrefType "journal-article" @default.
• W2114819486 hasAuthorship W2114819486A5003946700 @default.
• W2114819486 hasAuthorship W2114819486A5005729599 @default.
• W2114819486 hasAuthorship W2114819486A5005843927 @default.
• W2114819486 hasAuthorship W2114819486A5023991037 @default.
• W2114819486 hasAuthorship W2114819486A5024263685 @default.
• W2114819486 hasAuthorship W2114819486A5029415642 @default.
• W2114819486 hasAuthorship W2114819486A5037744319 @default.
• W2114819486 hasAuthorship W2114819486A5044446755 @default.
• W2114819486 hasAuthorship W2114819486A5050426287 @default.
• W2114819486 hasAuthorship W2114819486A5057499299 @default.
• W2114819486 hasAuthorship W2114819486A5065065990 @default.
• W2114819486 hasAuthorship W2114819486A5077674568 @default.
• W2114819486 hasAuthorship W2114819486A5083745890 @default.
• W2114819486 hasBestOaLocation W21148194861 @default.
• W2114819486 hasConcept C126322002 @default.
• W2114819486 hasConcept C126894567 @default.
• W2114819486 hasConcept C141071460 @default.
• W2114819486 hasConcept C143998085 @default.
• W2114819486 hasConcept C2776694085 @default.
• W2114819486 hasConcept C2776735609 @default.
• W2114819486 hasConcept C2778119113 @default.
• W2114819486 hasConcept C2778239845 @default.
• W2114819486 hasConcept C2778822529 @default.
• W2114819486 hasConcept C2780873365 @default.
• W2114819486 hasConcept C2781303535 @default.
• W2114819486 hasConcept C2781399356 @default.
• W2114819486 hasConcept C2781413609 @default.
• W2114819486 hasConcept C31760486 @default.
• W2114819486 hasConcept C71924100 @default.
• W2114819486 hasConcept C90924648 @default.
• W2114819486 hasConceptScore W2114819486C126322002 @default.
• W2114819486 hasConceptScore W2114819486C126894567 @default.

• next